U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
New solvent-free micronization technology expanded at the Darmstadt site in Germany
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Open a printable version of this pageEmail the URL of this page to a friend
Subscribe To Our Newsletter & Stay Updated
